Recombinant Human IL15 protein

中文名： 白介素15(IL15)重组蛋白
别名： IL15；Interleukin-15

货号: PA1000-5198

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	IL15
Uniprot No	P40933
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	49-162aa
氨基酸序列	NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVI SLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFL QSFVHIVQMFINTS
预测分子量	13 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于IL-15重组蛋白的3篇参考文献及其摘要概括：

---

1. **文献名称**：*"IL-15: A potential target for cancer immunotherapy"*

**作者**：Waldmann, T.A.

**摘要**：探讨IL-15在抗肿瘤免疫中的作用，强调其通过激活NK细胞和CD8+ T细胞增强免疫应答的机制，并与IL-2对比，指出IL-15在减少调节性T细胞抑制方面的潜在优势。

2. **文献名称**：*"Phase I trial of recombinant human IL-15 in patients with metastatic cancer"*

**作者**：Conlon, K.C., et al.

**摘要**：报告一项IL-15重组蛋白的I期临床试验，评估其在晚期实体瘤患者中的安全性和耐受性，发现剂量依赖性免疫激活效应，并观察到部分患者的肿瘤稳定。

3. **文献名称**：*"IL-15/IL-15Rα complex enhances NK cell-mediated antitumor activity in vivo"*

**作者**：Rubinstein, M.P., et al.

**摘要**：研究IL-15与IL-15Rα的复合物形式(IL-15 superagonist)在小鼠模型中的抗肿瘤效果，证明其通过延长IL-15半衰期和增强NK细胞活性显著抑制肿瘤生长。

---

以上文献涵盖基础机制、临床转化及药效优化方向，可作为IL-15研究的核心参考。

背景信息

Interleukin-15 (IL-15) is a cytokine belonging to the four-α-helix bundle family, sharing structural and functional similarities with IL-2. It plays critical roles in immune regulation, particularly in promoting the survival, proliferation, and activation of natural killer (NK) cells, CD8+ memory T cells, and innate lymphoid cells. Unlike IL-2. which primarily regulates effector T cell apoptosis, IL-15 sustains long-term immune cell maintenance, making it a key player in adaptive and innate immunity. Its receptor complex consists of IL-15Rα, IL-2Rβ, and the common γ-chain (γc), with trans-presentation by IL-15Rα being essential for effective signaling.

Recombinant IL-15 proteins are engineered using genetic modification techniques, often expressed in bacterial, yeast, or mammalian systems to ensure proper folding and post-translational modifications. These proteins retain the bioactive properties of native IL-15 and are widely used in research and therapeutic development. Preclinical studies highlight IL-15's potential in cancer immunotherapy, particularly for enhancing NK and T cell cytotoxicity against tumors. Clinical trials explore its use as a monotherapy or in combination with checkpoint inhibitors, adoptive cell therapies (e.g., CAR-T/NK cells), or vaccines.

However, challenges like short serum half-life and dose-limiting toxicity (e.g., vascular leak syndrome) have driven innovations in IL-15 delivery. Strategies include fusion with IL-15Rα (IL-15:IL-15Rα complexes), pegylation, or nanoparticle encapsulation to improve pharmacokinetics. Additionally, IL-15's dual role in promoting both pro-inflammatory and regulatory immune responses necessitates precise targeting to avoid autoimmune complications. Ongoing research aims to optimize IL-15-based therapies while balancing efficacy and safety for applications in oncology, infectious diseases, and immune modulation.